Empagliflozin Changes Urine Supersaturation by Decreasing pH and Increasing Citrate

… This post hoc analysis shows that SGLT2i may reduce kidney calciumcontaining stone risk by decreasing the RSR of CaP minerals in healthy subjects. This effect seems to be mediated by increased urinary citrate and reduced urinary pH. Prospective trials with kidney stone formers are needed to evaluate the effect of SGLT2i in secondary prevention of nephrolithiasis. 

Sodium–glucose cotransporter 2 inhibitors and risk of nephrolithiasis

…  Results We identified 24,290 and 19,576 eligible users of SGLT2Is and GLP1 RAs, respectively. After matching, 12,325 patient pairs remained. The median age was 61 years and median follow-up was 2.0 years. The nephrolithiasis rate was 2.0 per 1000 person-years in SGLT2I initiators compared with 4.0 per 1000 person-years in GLP1 RA initiators, with a rate … Leggi tutto

Meeting report of the “Symposium on kidney stones and mineral metabolism: calcium kidney stones in 2017”

A symposium on kidney stones and mineral metabolism held on December 2017 in Brussels, Belgium was the first international multidisciplinary conference of the International Collaborative Network on Kidney Stones and Mineral Metabolism. This meeting addressed epidemiology, underlying pathophysiological mechanisms, genetics, pathological, as well as clinical and research topics. The participants included clinicians and recognized experts … Leggi tutto

Kidney Stones Associate with Increased Risk for Myocardial Infarction

Kidney stones are a risk factor for chronic kidney disease (CKD), which, in turn, is a risk factor for myocardial infarction (MI). The objective of this study was to determine whether kidney stones associate with an increased risk for MI. We matched 4564 stone formers (1984 through 2003) on age and gender with 10,860 control … Leggi tutto